Neurocrine Biosciences reported results for the 2026 quarter with revenue of $959M and diluted EPS of $1.39, driven by product launches and volume growth that supported higher net income versus the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$959M$687.5M39.5% | Net income²$144.4M$107.5M34.3% | Diluted EPS³$1.39$1.0631.1% |
¹ Reported as “Total revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Total net product sales rose 41.7% year-to-date to $1.77B, supported by the CRENESSITY launch, INGREZZA volume growth and inclusion of VYKAT XR.
- CRENESSITY and INGREZZA saw strong demand with record new prescriptions and supportive multi-year clinical data.
- Acquisition of Soleno in May 2026 added VYKAT XR, expanding the company’s rare disease commercial portfolio and product mix.
- Company expanded commercial headcount and opened a new campus facility to support biologics, peptide and gene therapy programs; multiple clinical starts and positive Phase 3 data for CRENESSITY were reported.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.